BRCA1

EVENT - Empowering Women Through Knowledge; Humanise Health & GeneType Launch "Know Your Risk”

Retrieved on: 
Monday, April 8, 2024
Community, Genomics, Health, Genetic testing, GTG, Partnership, Knowledge, ASX, Security (finance), Risk, Krystal Barter, Woman, Risk assessment, Heart, Movement, BRCA1, Writing, Nursing

"Know Your Risk" is a movement towards empowering every woman with the knowledge to take charge of her health.

Key Points: 
  • "Know Your Risk" is a movement towards empowering every woman with the knowledge to take charge of her health.
  • Community Support: Be part of the launch of a "Know Your Risk" campaign, fostering a supportive community focused on empowering women to make informed decisions about their health.
  • Together with Humanise Health, a leading patient advocacy agency, we are at the forefront of advocating for preventative health and personalized health strategies.
  • This partnership for the "Know Your Risk" event underscores our collective dedication to empowering women with the knowledge to proactively manage their health.

Bionano Announces Publication of a Breast Cancer Study Showing that the Number of SVs Detected with OGM May Be Related to Prognosis, Tumor Progression and Chemotherapy Resistance

Retrieved on: 
Tuesday, March 19, 2024
Ovarian cancer, DNA repair, Breast, SAN, Neoplasm, DNA, HBOC, Doctor of Philosophy, Medicine, Genomics, Chromothripsis, SVS, Breast cancer, HRD, BRCA2, OGM, BRCA1, Drug resistance, Medical imaging

HBOC syndrome is estimated to cause 5-10% of all breast cancers and is commonly characterized by harmful germline mutations in the BRCA1 or BRCA2 genes.

Key Points: 
  • HBOC syndrome is estimated to cause 5-10% of all breast cancers and is commonly characterized by harmful germline mutations in the BRCA1 or BRCA2 genes.
  • The study authors selected OGM for this analysis due to its ability to detect multiple classes of SVs with genome-wide coverage, high resolution and accuracy.
  • Eight novel gene fusions were identified by OGM, including three that had not previously been detected by other methods of analysis.
  • “We are pleased to see the publication of this study, which highlights OGM as a promising tool for detecting novel variants in HBOC-related breast cancer that have oncogenic potential.

Nucleus Genomics launches to bring whole-genome sequencing to the public

Retrieved on: 
Monday, March 25, 2024
Technology, Research, Medical Devices, Genetics, Biotechnology, Health, Pharmaceutical, Science, Consumer Electronics, Human Genome Project, WGS, Blood pressure, Genomics, Certification, Informatics, Genetic testing, Nucleus, Risk, Human, PRS, DNA, Accreditation, Breast, CAP, Overalls, Facial muscles, Cancer, CLIA, Breast cancer, BRCA2, BMI, BRCA1, Vaccine

Nucleus Genomics , the next-generation genetic testing and analysis company, today announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone.

Key Points: 
  • Nucleus Genomics , the next-generation genetic testing and analysis company, today announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone.
  • Nucleus will also offer pre-orders for its premium clinical-grade whole-genome sequencing (WGS) service, in which a customer’s entire set of DNA will be read and analyzed.
  • Nucleus is proud to sequence all customer samples in the U.S. on Illumina’s NovaSeq X Plus, the sequencing company’s newest and most innovative high-throughput sequencing instrument.
  • Working with Illumina, Nucleus is leveraging this latest sequencing technology to make WGS broadly accessible to power personalized healthcare.

INTERACT COALITION FORMED TO ADVANCE PATIENT ACCESS TO GENETIC TESTING FOR HEREDITARY CANCER RISK

Retrieved on: 
Wednesday, April 3, 2024
Ovarian cancer, Quest Diagnostics, Gene, Mutation, Genetic testing, Chemoprophylaxis, Incidence, Risk, Genetics, Education, SAN, Patient, Policy, Cancer, Hereditary nonpolyposis colorectal cancer, Salpingo-oophorectomy, Mastectomy, Breast cancer, Therapy, BRCA2, Physician, BRCA1, Cancer syndrome, Human, Vaccine

The coalition seeks to provide a collective voice in support of the progression of medical professional and industry guidelines for genetic testing for inherited mutations that increase cancer risk.

Key Points: 
  • The coalition seeks to provide a collective voice in support of the progression of medical professional and industry guidelines for genetic testing for inherited mutations that increase cancer risk.
  • With growing insight into the role of genetic testing in cancer risk management and treatment, the population of individuals who benefit from knowing their genetic mutation status continues to increase.
  • Hereditary cancer genetic testing has been shown to improve outcomes by identifying those most at risk and informing management strategies.
  • Among the challenges to broadening access to genetic testing for hereditary cancer risk is a time lag in updating guidelines and medical policies after the publication of new medical literature.

Nucleus Genomics launches to bring whole-genome sequencing to the public

Retrieved on: 
Monday, March 25, 2024
Human Genome Project, WGS, Blood pressure, Genomics, Health, Certification, Informatics, Founders Fund, Genetic testing, Risk, Genetics, Human, PRS, DNA, Accreditation, Breast, CAP, Overalls, Facial muscles, Cancer, CLIA, Breast cancer, BRCA2, BMI, BRCA1

NEW YORK, March 25, 2024 /PRNewswire/ -- Nucleus Genomics, the next-generation genetic testing and analysis company, today announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone.

Key Points: 
  • Nucleus further personalizes these risk assessments by integrating personal and lifestyle factors into their analysis — such as age, cholesterol levels, blood pressure, and BMI.
  • Nucleus will also offer pre-orders for its premium clinical-grade whole-genome sequencing (WGS) service, in which a customer's entire set of DNA will be read and analyzed.
  • Nucleus is proud to sequence all customer samples in the U.S. on Illumina's NovaSeq X Plus, the sequencing company's newest and most innovative high-throughput sequencing instrument.
  • Working with Illumina, Nucleus is leveraging this latest sequencing technology to make WGS broadly accessible to power personalized healthcare.

Labcorp Presents New Research Demonstrating Clinical Impact of Precision Diagnostics in Guiding Biomarker-targeted Therapies for Patients with Epithelial Ovarian Cancer

Retrieved on: 
Saturday, March 16, 2024
Diagnosis, Ovarian cancer, MIRV, Mutation, Health, BRCA, Science, Disease, Partnership, Patient, Education, Glomus tumor, Roche, Biomarker, Neoplasm, Research, Cancer, EOC, Recombinant DNA, Woman, HRP, PARP, TTD, Fibroadenoma, HRD, Mirvetuximab soravtansine, BRCA2, Recurrence, LH, BRCA1, ADP, Pharmaceutical industry

BURLINGTON, N.C., March 16, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today presented the results from two studies at the 2024 SGO Annual Meeting on Women's Cancer. The studies demonstrate the value of biomarker testing in closing testing gaps and guiding targeted therapies for patients with epithelial ovarian cancer (EOC).

Key Points: 
  • The studies demonstrate the value of biomarker testing in closing testing gaps and guiding targeted therapies for patients with epithelial ovarian cancer (EOC).
  • Labcorp researchers conducted two studies to generate further evidence of the value of comprehensive genomic profiling to drive guideline-compliant testing that enables increased patient access to targeted therapies for improved outcomes.
  • When combined, the results of BRCA and HRD testing can determine which patients are most likely to benefit from treatment with poly-ADP ribose polymerase (PARP) inhibitors.
  • "This research emphasizes the power of comprehensive biomarker testing in advancing the treatment of ovarian cancer.

UT Health San Antonio secures $16.4 million from CPRIT over six months, adding transformative expertise, bolstering cancer research

Retrieved on: 
Friday, March 8, 2024
Doctor of Philosophy, Education, MD, Drug development, DNA repair, National Cancer Institute, Breast, University, RNA, Research institute, Ovarian cancer, Cell Systems, Health, Genetics, Anatomy, Biochemistry, Bangladesh Technical Education Board, Algorithm, Adolescence, Nursing, Neoplasm, Kitagawa, Faculty, Dentistry, HPV, Child, DNA, Chromatin, Therapy, SAN, National Institutes of Health, Mentorship, Chromosome instability, Doctor of Pharmacy, Structural biology, Vaccination, Cancer Research Institute, Molecular medicine, News, Laboratory, Research, University of Texas System, Cedars-Sinai Medical Center, Survivor, BRCA2, Cell, Howard Hughes Medical Institute, School, Cancer prevention, Luan, BRCA1, Patient, Teaching, Ewing sarcoma, Cancer, Public, Vaccine

SAN ANTONIO, March 7, 2024 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) (https://uthscsa.edu/) has secured approximately $16.4 million in funding from the Cancer Prevention and Research Institute of Texas (https://www.cprit.state.tx.us/about-us) the past six months, attracting three top cancer researchers and advancing child and adolescent cancer research.

Key Points: 
  • SAN ANTONIO, March 7, 2024 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) ( https://uthscsa.edu/ ) has secured approximately $16.4 million in funding from the Cancer Prevention and Research Institute of Texas ( https://www.cprit.state.tx.us/about-us ) the past six months, attracting three top cancer researchers and advancing child and adolescent cancer research.
  • The Mays Cancer Center at UT Health San Antonio ( https://cancer.uthscsa.edu/ ) is one of only four National Cancer Institute-designated Cancer Centers in Texas.
  • The Mays Cancer Center provides leading-edge cancer care, propels innovative cancer research and educates the next generation of leaders to end cancer in South Texas.
  • The Greehey Children's Cancer Research Institute ( https://cancer.uthscsa.edu/gccri ) is one of only two institutes in the United States dedicated solely to pediatric cancer research.

Human medicines European public assessment report (EPAR): Lynparza, olaparib, Date of authorisation: 16/12/2014, Revision: 24, Status: Authorised

Retrieved on: 
Friday, January 5, 2024
Marketing, Platinum, INN, Risk, HER2, Leukopenia, Heartburn, Woman, BRCA, Man, Nausea, DNA, Cancer, Neoplasm, Mutation, Pancreatic cancer, ADP, Prostate, Anatomy, Cell division, Cough, IIA, Diarrhea, Prostate cancer, HRD, Fatigue, Breast cancer, ATC, Platelet, Pancreas, Prednisone, Disease, Genome, Abdomen, Testosterone, PARP, Neutrophil, Bevacizumab, Appetite, Human, Anemia, Patient, Medical Subject Headings, Peritoneum, International, FIGO, Tubing (recreation), Neutropenia, Language, Castration, Dizziness, Thrombocytopenia, BRCA1, Gene, Tablet, Select, Time, Vomiting, Ovary, Prednisolone, X-ray, Ovarian cancer, Headache, BRCA2, European Medicines Agency, Indigestion, Periodic breathing, Birth control

Human medicines European public assessment report (EPAR): Lynparza, olaparib, Date of authorisation: 16/12/2014, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Lynparza, olaparib, Date of authorisation: 16/12/2014, Revision: 24, Status: Authorised

City of Hope Doctors and Scientists Present Innovative Research at Largest Gathering on Breast Cancer Research

Retrieved on: 
Friday, December 8, 2023
Research, Women, Genetics, Health, Consumer, Pharmaceutical, General Health, Science, Oncology, BRCA1, Perception, Woman, WHI, Prevalence, City, Incidence, Menopause, Risk, Breast cancer, Cardiovascular disease, Cancer, Patient, Multimedia, History, Hispanic, INSPIRE, Hysterectomy, Genetic testing, Data collection, BRCA2, Hormone replacement therapy, Prognosis, Standard of care, Ovarian cancer, Diagnosis, African Americans, Uterus, Progesterone, BRCA, Physician, Mutation, Medical imaging, Birth control, Hope

City of Hope, one of the largest cancer research and treatment organizations in the United States, will present innovative research at this year’s San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 5 to 9 in San Antonio, Texas.

Key Points: 
  • City of Hope, one of the largest cancer research and treatment organizations in the United States, will present innovative research at this year’s San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 5 to 9 in San Antonio, Texas.
  • (Photo: Business Wire)
    Each year, about 10,000 physicians, scientists and other health care professionals attend the annual conference, which examines new breast cancer research and helps guide treatment of patients nationwide.
  • It is the largest and most prestigious scientific gathering on breast cancer research.
  • Women who have BRCA1 tend to have more aggressive breast cancers and the mutation can also cause ovarian cancer.

Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients

Retrieved on: 
Friday, December 1, 2023
BRCA1, HR, PALB2, Magnetic resonance imaging, Nottingham Prognostic Index, Woman, Research, Prevalence, Gene, ICI, Breast cancer, Cancer, DS, Risk, Disease, Epistasis, Patient, Tumor microenvironment, DCIS, Exact sciences, Ductal carcinoma, Gene expression, Genetic testing, Messenger, BRCA2, NPI, HER2, MammaPrint, Oncotype (Denmark), Medicine, Biomarker, ERBB2, Summary, Neoplasm, Recurrence, Clinical, TNBC, Medical imaging, Birth control, Vaccine, MD

"Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients.

Key Points: 
  • "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients.
  • In cooperation with several leading breast cancer research organizations, Exact Sciences will present late-breaking data and a study included in the SABCS press program.
  • Results from Puerto Rico will also detail germline findings for a cohort of women, most of whom had a personal or familial history of breast cancer.
  • Exact Sciences will also host a discussion about the Oncotype DX Breast Recurrence Score test and the RSClin® Tool.